Literature DB >> 18938179

Impact of plasma-protein binding on receptor occupancy: an analytical description.

Lambertus A Peletier1, Neil Benson, Piet H van der Graaf.   

Abstract

In this paper we analyse the dynamics of an inhibitor I which can either bind to a receptor R or to a plasma protein P. Assuming typical association and dissociation rates, we find that after an initial dose of inhibitor, there are three time scales: a short one, measured in fractions of seconds, in which the inhibitor concentration and the plasma-protein complex jump to quasi-stationary values, a medium one, measured in seconds in which the receptor complex rises to an equilibrium value and a large one, measured in hours in which the inhibitor-receptor complex slowly drops down to zero. We show that the average receptor occupancy, the pharmacologically relevant quantity, taken over, say, 24h reaches a maximal value for a specific value of the plasma-protein binding constant. Potentially, understanding and exploiting this optimum could be of great interest to those involved in drug discovery and development.

Mesh:

Substances:

Year:  2008        PMID: 18938179     DOI: 10.1016/j.jtbi.2008.09.014

Source DB:  PubMed          Journal:  J Theor Biol        ISSN: 0022-5193            Impact factor:   2.691


  11 in total

Review 1.  The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery.

Authors:  Dennis A Smith; Li Di; Edward H Kerns
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

2.  Mathematical analysis and drug exposure evaluation of pharmacokinetic models with endogenous production and simultaneous first-order and Michaelis-Menten elimination: the case of single dose.

Authors:  Xiaotian Wu; Fahima Nekka; Jun Li
Journal:  J Pharmacokinet Pharmacodyn       Date:  2018-07-09       Impact factor: 2.745

3.  Consideration of the Unbound Drug Concentration in Enzyme Kinetics.

Authors:  Nigel J Waters; R Scott Obach; Li Di
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

5.  Estimation of binding rate constants using a simultaneous mixed-effects method: application to monoamine transporter reuptake inhibitor reboxetine.

Authors:  Neil Benson; Nelleke Snelder; Bart Ploeger; Carolyn Napier; Harriet Sale; Nigel J M Birdsall; Richard P Butt; Piet H van der Graaf
Journal:  Br J Pharmacol       Date:  2010-05       Impact factor: 8.739

6.  Coping with time scales in disease systems analysis: application to bone remodeling.

Authors:  Stephan Schmidt; Teun M Post; Lambertus A Peletier; Massoud A Boroujerdi; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-26       Impact factor: 2.745

7.  Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.

Authors:  Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-01       Impact factor: 2.745

8.  Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study.

Authors:  S Bakshi; E C de Lange; P H van der Graaf; M Danhof; L A Peletier
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-07-20

9.  Impact of saturable distribution in compartmental PK models: dynamics and practical use.

Authors:  Lambertus A Peletier; Willem de Winter
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-03       Impact factor: 2.745

10.  Building Optimal Three-Drug Combination Chemotherapy Regimens To Eradicate Mycobacterium tuberculosis in Its Slow-Growth Acid Phase.

Authors:  Sarah Kim; Walter M Yamada; Brandon Duncanson; Jocelyn Nole; Stephanie Rogers; Sarah Parker; Meredith Bacci; Nino Mtchedlidze; Charles A Peloquin; Arnold Louie; Stephan Schmidt; George L Drusano; Michael N Neely
Journal:  Antimicrob Agents Chemother       Date:  2021-08-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.